Evommune, Inc. EVMN · Stock Open Evommune, Inc. in new tab

11.59 USD

Add to portfolio

EPS

-2.11

P/B

1.31

ROE

-44.95

Target Price

31.14 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Evommune, Inc. (EVMN)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Evommune, Inc. Analysis (EVMN)

Official Website Stock

Is Evommune, Inc. a good investment? Evommune, Inc. (EVMN) is currently trading at 11.59 USD. Market analysts have a consensus price target of 31.14 USD. This suggests a potential upside from current levels.

Earnings Schedule: Evommune, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -3.24.

Investor FAQ

Does Evommune, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Evommune, Inc.?

Evommune, Inc. is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -2.11.

Company Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Trades

No dividend information available for this instrument.

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.